5 completed, 2 terminated, 2 withdrawn, 1 not yet recruiting. 11 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 5, Terminated 2, Withdrawn 2, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
Follow Pemphigoid, Bullous: new trials by email Literature Review of Pemphigoid, Bullous trials Research Report on Pemphigoid, Bullous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid Stapokibart injection, Placebo - Bullous Pemphigoid (BP) | Phase 3 | Not yet recruiting | Chengdu Kangnuoxing Biopharma,Inc. | 200 | 2025-11-11 | 2025-10-07 |
| A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid efgartigimod PH20 SC, Prednisone - Bullous Pemphigoid | Phase 3 | Terminated | argenx | 64 | 2023-03-22 | 2026-02-25 |
| Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid Ozonated olive oil, Topical garamycin cream - Pemphigus Vulgaris, Bullous Pemphigoid | Phase 3 | Unknown | Cairo University | 30 | 2022-11-01 | 2022-11-08 |
| A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid efgartigimod PH20 SC, placebo, Prednisone - Bullous Pemphigoid | Phase 2 / Phase 3 | Completed | argenx | 98 | 2022-06-09 | 2025-10-23 |
| Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) nomacopan (rVA576), Placebo - Bullous Pemphigoid | Phase 3 | Withdrawn | AKARI Therapeutics | 2022-05-06 | 2025-04-09 | |
| A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. Benralizumab, Placebo - Bullous Pemphigoid | Phase 3 | Terminated | AstraZeneca | 67 | 2021-03-31 | 2024-11-29 |
| A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid dupilumab, Matching Placebo, Oral corticosteroids (OCS) - Bullous Pemphigoid | Phase 2 / Phase 3 | Completed | Regeneron Pharmaceuticals | 106 | 2020-10-28 | 2026-06-18 |
| Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid Rituximab combined with Omalizumab - Bullous Pemphigoid | Phase 3 | Withdrawn | University of California, Davis | 2017-03-01 | 2024-07-03 | |
| Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids NPB-01, Placebo - Bullous Pemphigoid | Phase 3 | Completed | Nihon Pharmaceutical Co., Ltd | 56 | 2011-08-01 | 2013-10-16 |
| Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid Mabthera - Bullous Pemphigoid | Phase 3 | Completed | University Hospital, Rouen | 18 | 2008-12-01 | 2026-04-16 |
| Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid clobetasol propionate + Methotrexate, clobetasol propionate alone - Bullous Pemphigoid | Phase 3 | Completed | University Hospital, Montpellier | 322 | 2008-01-22 | 2026-04-24 |
Blister (1) · Eosinophilia (1) · Pemphigus (1) · Pruritus (1) · Rare Diseases (1) · Urticaria (1)
Autoimmune Diseases (11) · Immune System Diseases (11) · Skin Diseases (11) · Skin Diseases, Vesiculobullous (11) · Skin and Connective Tissue Diseases (11) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Leukocyte Disorders (1) · Pathologic Processes (1) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Prednisone (2) · Adrenal Cortex Hormones (1) · Clobetasol (1) · Methotrexate (1) · Omalizumab (1) · Rituximab (1) · benralizumab (1) · dupilumab (1)
argenx (2) · AKARI Therapeutics (1) · AstraZeneca (1) · Cairo University (1) · Chengdu Kangnuoxing Biopharma,Inc. (1) · Nihon Pharmaceutical Co., Ltd (1) · Regeneron Pharmaceuticals (1) · University Hospital, Montpellier (1) · University Hospital, Rouen (1) · University of California, Davis (1)
United States (6) · France (5) · Germany (5) · Japan (5) · Australia (4) · China (4) · Israel (4) · Spain (4) · Bulgaria (3) · Greece (3) · Italy (3) · Netherlands (3) · Poland (3) · Croatia (2) · Czechia (2)
Emanual Maverakis, MD (1) · Hang Li, Chief physician (1) · Mohamed El-Shazly, MD (1) · Olivier Dereure, MD, PhD (1)
PMID 30837635, PMID 38443648, PMID 41807108
2019 (1), 2023 (1)